Although it appears that chronic RT beneficially alters factors in the IGF axis to reduce bioavailable IGF-1, larger RCTs are needed to ascertain the clinical impact of these results on the progression of prostate cancer. This evidence concerns the gene IGF1 and prostate carcinoma.